MLV & Co Raises Price Target On Xencor On Attractive Investment Opportunity
In a report published Wednesday, MLV & Co analyst Arlinda Lee reiterated a Buy rating on Xencor (NASDAQ: XNCR), and raised the price target from $18.00 to $22.00.
In the report, MLV & Co noted, “After reviewing IgG4-Related Disease (IgG4-RD) and XmAb5871 literature, we are more confident in XmAb5871's potential for success and increase our estimates for its probability of reaching market to 40% (prior 26%) and peak sales to $430M (prior $362M). Our XmAb5871 valuation increases to $9e/share (prior $5e/share). We reiterate our Buy rating and increase our PT to $22.”
Xencor closed on Tuesday at $16.98.
Latest Ratings for XNCR
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | HC Wainwright & Co. | Maintains | Buy | |
| Feb 2022 | BMO Capital | Initiates Coverage On | Outperform | |
| Dec 2021 | HC Wainwright & Co. | Initiates Coverage On | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Arlinda Lee MLV & CoAnalyst Color Price Target Analyst Ratings
